Previous close | 0.1000 |
Open | 0.1050 |
Bid | 0.1000 x 3350000 |
Ask | 0.1050 x 10984500 |
Day's range | 0.1050 - 0.1050 |
52-week range | 0.0650 - 0.1700 |
Volume | |
Avg. volume | 1,422,025 |
Market cap | 23.919M |
Beta (5Y monthly) | 1.14 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT. TRAVELAN® BOUND FOR PHASE 3 CLINICAL TRIALSExp
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on Walmart.com MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immu
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint)66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secon